ASP Isotopes Targets 2026 Commercial Scale-Up and Strategic QLE Spin-Off
ASP Isotopes CEO Paul Mann has outlined a 2026 commercialization roadmap, highlighting imminent Silicon-28 shipments for the semiconductor industry and a strategic spin-off of its Quantum Laser Enrichment (QLE) division. The transition marks a shift from R&D to high-value industrial production across the semiconductor, medical, and nuclear sectors.